Italy
Medizinprodukt-Marktintelligenz für Italy. Regulatorische Änderungen, Wettbewerber und Beschaffungstrends.
Neueste Signale
A completed study compared outcomes of a new curved cutter stapler vs. traditional staplers in obstructed defecation surgery.
The OAK device evaluates fall risk in the elderly using virtual reality, showing accuracy against CDC standards.
XONRID is a topical gel that prevents radiation-induced dermatitis in head and neck cancer patients.
A study compares a disposable negative pressure wound device to standard dressings for infection rates post-pancreatic surgery.
A clinical investigation is recruiting to evaluate ArToFILL for osteoarticular pain management.
The BRIDGE/EMPATIA exoskeleton study assessed its fit, safety, and usability for patients with muscular dystrophy.
A completed study evaluated the usability and safety of the ENDONEB device for surgical applications.
A new Class IIb medical device for proctological disorders has completed a study comparing it to placebo.
A clinical trial is recruiting to evaluate Vagitab-T's effectiveness for bacterial vaginosis in Europe.
A clinical trial is recruiting to assess Agilik's impact on knee extension in children with cerebral palsy.
A completed trial evaluated a Novel Venous Cannula's safety and performance in cardiac surgery with 42 participants.
A study compares cortisone to a new hydrolyzed collagen device for hip arthroscopy in FAI patients.
A completed study compared a pullulan-based device with silicone gel on post-surgical scars.
Italy's new early feasibility study guidelines will impact medical device innovation across Europe.
GENERAL MEDICAL MERATE S.P.A. registered 5 medical devices with the FDA under product code IZF.
The study will assess the efficacy of Hilotherm® in reducing peripheral neuropathy from Taxol in breast cancer patients.
A study assessed an ankle mobilization device's efficacy for pediatric brain injury rehabilitation, focusing on safety and performance.
A completed study evaluated a novel upper limb rehabilitation device for stroke patients during COVID-19.
The study evaluates Celegyn®, a CE marked vaginal cream, for treating vulvovaginal atrophy in women.
A trial evaluates the efficacy of Sollievo Fisiolax for chronic constipation over 28 days.